CASI Pharmeceuticals

Press Release

September 07, 2017

CASI Provides Pipeline Development Update

View All
Casi Pharmaceuticals

CASI Pharmaceuticals CEO Ken K. Ren, PhD rang the closing bell at NASDAQ on Thursday, June 11, 2015 4PM.

About Us

CASI is a biopharmaceutical company focused on the acquisition, development, and commercialization of innovative therapeutics addressing cancer and other unmet medical needs for the global market, with a focus on China and the U.S.

Learn More

Presentation

Clinical Safety and Efficacy of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated, Locally Advanced or Metastatic Triple-Negative Breast Cancer

Download →

Presentation

Rodman & Renshaw 19th Annual Global Investment Conference

Download →

Presentation

Phase II clinical and molecular trial of oral ENMD-2076 in clear cell ovarian cancer (CCOC): A study of the Princess Margaret Phase 2 consortium

Download →

Receive press releases via email